Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | GHSR | Q92847 | 5/20 | 0.38 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1564581 | 1.00 | HPGD (0.39) | HPGDHTTGHSRCHEK1ALDH1A1 | |
| SCHEMBL18226165 | 1.00 | HPGD (0.39) | HPGDHTTGHSRCHEK1ALDH1A1 | |
| SCHEMBL477321 | 0.94 | HPGD (0.35) | HPGDGHSRALDH1A1 | |
| SCHEMBL1248249 | 0.94 | HPGD (0.35) | HPGDGHSRALDH1A1 | |
| SCHEMBL1421166 | 0.94 | HPGD (0.35) | HPGDGHSRALDH1A1 | |
| Hydrochloric Acid SCHEMBL4738655 | 0.92 | KDM1A (0.34) | HPGDGHSRALDH1A1 | |
| Hydrochloric Acid SCHEMBL3487633 | 0.92 | KDM1A (0.34) | HPGDGHSRALDH1A1 | |
| SCHEMBL794096 | 0.85 | — | — | |
| SCHEMBL798194 | 0.85 | — | — | |
| SCHEMBL8238 | 0.85 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 68 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260007684-A1 | AMIDE DERIVATIVES FOR INHIBITING NLRP3 AND USES THEREOF | VENTUS THERAPEUTICS U S INC (US) | 2026-01-08 | — | — | US | disclosed |
| US-20230339922-A1 | COVALENT EGFR INHIBITORS AND METHODS OF USE THEREOF | DANA FARBER CANCER INST INC (US) | 2023-10-26 | — | — | US | disclosed |
| CN-116917279-A | BTK inhibitors | 渤健马萨诸塞州股份有限公司 | 2023-10-20 | — | — | CN | disclosed |
| US-11787788-B2 | Benzimidazole derivatives, and pharmaceutical compositions and methods of use thereof | CAPELLA THERAPEUTICS, INC. (US) | 2023-10-17 | — | — | US | disclosed |
| US-20230295137-A1 | COVALENT EGFR INHIBITORS AND METHODS OF USE THEREOF | DANA FARBER CANCER INST INC (US) | 2023-09-21 | — | — | US | disclosed |
| US-20230271938-A1 | BENZIMIDAZOLES FOR USE IN THE TREATMENT OF CANCER AND INFLAMMATORY DISEASES | CAPELLA THERAPEUTICS, INC. | 2023-08-31 | — | — | US | disclosed |
| EP-4225309-A1 | COVALENT EGFR INHIBITORS AND METHODS OF USE THEREOF | Dana-Farber Cancer Institute, Inc. (US) | 2023-08-16 | — | — | EP | disclosed |
| EP-4225288-A1 | COVALENT EGFR INHIBITORS AND METHODS OF USE THEREOF | Dana-Farber Cancer Institute, Inc. (US) | 2023-08-16 | — | — | EP | disclosed |
| EP-4192587-A1 | BTK INHIBITORS | Biogen MA Inc. (US) | 2023-06-14 | — | — | EP | disclosed |
| US-11661410-B2 | Tricyclic compounds as histone methyltransferase inhibitors | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2023-05-30 | — | — | US | disclosed |
| EP-2227460-B1 | THERAPEUTIC OXY-PHENYL-ARYL COMPOUNDS AND THEIR USE | CANCER REC TECH LTD (GB) | 2012-06-20 | — | — | EP | disclosed |
| WO-2012058645-A1 | HETEROCYCLIC TYROSINE KINASE INHIBITORS | BIOGEN IDEC MA INC. (US) | 2012-05-03 | — | — | WO | disclosed |
| EP-2344494-A1 | AMINOTRIAZOLOPYRIDINES AND THEIR USE AS KINASE INHIBITORS | Signal Pharmaceuticals, LLC (US) | 2011-07-20 | — | — | EP | disclosed |
| EP-2227460-A1 | THERAPEUTIC OXY-PHENYL-ARYL COMPOUNDS AND THEIR USE | Cancer Research Technology Limited (GB) | 2010-09-15 | — | — | EP | disclosed |
| US-20100093698-A1 | AMINOTRIAZOLOPYRIDINES, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | SIGNAL PHARMACEUTICALS, LLC | 2010-04-15 | — | — | US | disclosed |
| WO-2010027500-A1 | AMINOTRIAZOLOPYRIDINES AND THEIR USE AS KINASE INHIBITORS | SIGNAL PHARMACEUTICALS, LLC (US) | 2010-03-11 | — | — | WO | disclosed |
| US-20100056497-A1 | AMIDE DERIVATIVE | DAINIPPON SUMITOMO PHARMA CO., LTD (JP) | 2010-03-04 | — | — | US | disclosed |
| EP-2119702-A1 | AMIDE DERIVATIVE | Dainippon Sumitomo Pharma Co., Ltd. (JP) | 2009-11-18 | — | — | EP | disclosed |
| WO-2009053694-A1 | THERAPEUTIC OXY-PHENYL-ARYL COMPOUNDS AND THEIR USE | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2009-04-30 | — | — | WO | disclosed |
| CN-1867557-A | Substitute thiophenes and uses therof | ASTRAZENECA AB (SE) | 2006-11-22 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230295137-A1 | COVALENT EGFR INHIBITORS AND METHODS OF USE THEREOF | EGFR, ERBB2, ERBB3 | HPGD 1652/4885HTT 3980/4885GHSR 2515/4885 |
| US-11787788-B2 | Benzimidazole derivatives, and pharmaceutical compositions and methods of use thereof | CCNI, CYP2C19, PHB1 | HPGD 86/4885HTT 2411/4885GHSR 2702/4885 |
| US-11661410-B2 | Tricyclic compounds as histone methyltransferase inhibitors | EHMT1, EHMT2, BMI1 | HPGD 3208/4885HTT 175/4885GHSR 2736/4885 |
| US-20230339922-A1 | COVALENT EGFR INHIBITORS AND METHODS OF USE THEREOF | EGFR, ERBB2, ERBB3 | HPGD 1652/4885HTT 3980/4885GHSR 2515/4885 |
| US-20100093698-A1 | AMINOTRIAZOLOPYRIDINES, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | MAP3K2, MAP3K1, MAP3K3 | HPGD 1179/4885HTT 1602/4885GHSR 3740/4885 |
| US-20100056497-A1 | AMIDE DERIVATIVE | REN, AGTR1, AGTR2 | HPGD 1367/4885HTT 2910/4885GHSR 106/4885 |
| US-20230271938-A1 | BENZIMIDAZOLES FOR USE IN THE TREATMENT OF CANCER AND INFLAMMATORY DISEASES | CHKB, CHKA, CHUK | HPGD 1013/4885HTT 4410/4885GHSR 3844/4885 |
| US-20260007684-A1 | AMIDE DERIVATIVES FOR INHIBITING NLRP3 AND USES THEREOF | NOD1, NLRP3, NOD2 | HPGD 2099/4885HTT 755/4885GHSR 1080/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.